High prevalence of low bone mass and associated factors in Korean HIV-positive male patients undergoing antiretroviral therapy

Pyoeng Gyun Choe*, Hyung Jin Choi†, Nak-Hyun Kim, Wan Beom Park, Kyoung-Ho Song, Ji Hwan Bang, Eu Suk Kim, Sang Won Park, Hong Bin Kim, Myoung-don Oh and Nam Joong Kim§

*Corresponding author: Nam Joong Kim, Department of Internal Medicine, Seoul National University College of Medicine, 103 Daehak-ro, Jongro-gu, Seoul 110-744, Republic of Korea. Tel: +82 2 2072 0835. Fax: +82 2 762 9662. (molder@unitel.co.kr)
†These authors contributed equally to this work.
§Present Affiliation: Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Republic of Korea.

Abstract

Introduction: Low bone mass is prevalent in HIV-positive patients. However, compared to Western countries, less is known about HIV-associated osteopenia in Asian populations.

Methods: We performed a cross-sectional survey in Seoul National University Hospital from December 2011 to May 2012. We measured bone mineral density using central dual energy X-ray absorptiometry, with consent, in male HIV-positive patients, aged 40 years and older. Diagnosis of low bone mass was made using International Society for Clinical Densitometry Z-score criteria in the 40–49 years age group and World Health Organization T-score criteria in the >50 years age group. The data were compared with those of a community-based cohort in Korea.

Results: Eighty-four HIV-positive male patients were included in this study. Median age was 49 (interquartile range [IQR], 45–56) years, and median body mass index (BMI) was 22.6 (IQR, 20.9–24.4). Viral suppression was achieved in 75 (89.3%) patients and median duration of antiretroviral therapy was 71 (IQR, 36–120) months. The overall prevalence of low bone mass was 16.7% in the 40–49 years age group and 54.8% in the >50 years age group. Our cohort had significantly lower bone mass at the femur neck and total hip than HIV-negative Koreans in the 40–49 years age group. Low bone mass was significantly associated with low BMI, and a high level of serum carboxy-terminal collagen crosslinks, but was not associated with antiretroviral regimen or duration of antiretroviral therapy.

Conclusions: Low bone mass is prevalent in Korean HIV-positive males undergoing antiretroviral therapy, and may be associated with increased bone resorption.

Keywords: HIV; AIDS; osteopenia; osteoporosis.

Introduction

The advent of combination antiretroviral therapy (CART) has improved the prognosis of patients infected with HIV [1]. Long-term CART is associated with several metabolic complications including lipodystrophy, insulin resistance, diabetes and dyslipidemia [2]. It is also well known that low bone mass is prevalent in HIV-positive patients [3]. In one meta-analysis, osteoporosis was three times more prevalent among HIV-positive patients than among HIV-negative controls, and was especially common among those receiving antiretroviral therapy [4].

The prevalence of low bone mass may vary in different ethnic groups, and less is known about the characteristics of low bone mass in Asian HIV-positive patients than in Western patients. Considering that there is a marked predominance of men in the clinic where this study was conducted, and that gender is an important risk factor for low bone mass, we chose to include only male patients. The present study was undertaken to investigate the prevalence of, and risk factors for, low bone mass in Korean HIV-positive males undergoing antiretroviral therapy.

Methods

Study population

This cross-sectional study included HIV-positive male patients over 40 years old who underwent CART for at least three months at Seoul National University Hospital. A board-certified infectious disease specialist took a complete history from all participants. Demographic data (sex, ethnicity and date of birth), HIV exposure category (men who have sex with men [MSM], heterosexual), life style (smoking, alcohol consumption and physical activity), nadir CD4 cell count, current CD4 cell count and history of CART were recorded. Serum level of 25(OH) Vitamin D₃, parathyroid hormone, carboxy-terminal collagen crosslinks (CTX), bone-specific alkaline phosphatase (ALP), total testosterone and free
testosterone were measured for each participant. Serum CTX level was measured by electrochemiluminescence immunoassay using the Elecsys® β-Crosslaps serum assay kit (Roche Diagnostics). The study protocol was in accordance with institutional guidelines and approved by an institutional review board. Informed consent was obtained from the study participants.

**Measurements of anthropometric parameters and BMD**

Height and body weight were measured by standard methods in light clothes. Body mass index (BMI) was calculated as weight divided by height squared (kg/m²). Bone mineral density (BMD) (g/cm²) measurements at central skeletal sites (lumbar spine, femoral neck and total hip) were obtained using dual energy X-ray absorptiometry (Lunar Prodigy, GE Medical System). Diagnosis of low bone mass was made using the International Society for Clinical Densitometry (ISCD) Z-score criteria (low BMD for chronological age, Z-score \( \leq -2.0 \)) and the World Health Organization (WHO) T-score criteria (Osteopenia, \( -2.5 < T\text{-score} \leq -1.0 \); Osteoporosis, T-score \( \leq -2.5 \) ) [5]. For comparison with the general population, the BMD of subjects in a representative Korean community-based cohort was used [6]. Both the HIV-positive study group and the HIV-negative general population group used the same Lunar Prodigy machine with the same software (Encore, GE) and the same manufacturer-provided Korean reference.

**Statistics**

BMD differences were analyzed using Student’s t-test. Risk factors for low bone mass were analyzed using a linear regression model with BMD as the dependent variable. Additional analysis was performed using binary logistic regression model with any BMD T-score \( < -1.0 \) as the dependent variable and odds ratios per one standard deviation increment were shown for continuous variables. All significance tests were two-sided, and data analyses were performed with SPSS software (version 19.0; SPSS Inc., Chicago, IL, USA).

**Results**

A total of 84 HIV-positive patients were included in this study. All were male, and 39 (46.4%) of them had the risk factors of homosexual behaviour. All were Korean, and median age was 49 years (IQR 45–56) (Table 1). Median CD4 cell count was 531 cells/µL (IQR, 345–762), and 75 (89.3%) patients had an HIV RNA level < 40 copies/mL. Median duration of antiretroviral therapy was 71 months (IQR, 36–120). Fifty-five (65.5%) of the subjects had vitamin D deficiency.

The overall prevalence of low bone mass was 16.7% in the 40–49 years age group and 54.8% in the > 50 years age group (Table 2). Compared with HIV-negative Koreans, the subjects in our cohort with HIV infection had significantly lower bone mass at femur neck and total hip in the 40–49 years age group (Figure 1B and 1C). In the 50–59 year age group, subjects with HIV infection had significantly lower bone mass at the femur neck than HIV-negative Koreans. There was no significant difference in the BMD at lumbar spine between HIV-negative Koreans and our subjects.

The association between BMD and other factors was investigated. There was no significant association between

| Table 1. Demographics and clinical characteristics of the study participants |
|---------------------------------|------------------|
| Characteristics                  | Study participants |
| Age, median years (IQR)          | 49 (45–56) |
| Age group, n (%)                 |                  |
| 40–49                           | 42 (50.0) |
| 50–59                           | 29 (34.5) |
| 60–69                           | 13 (15.5) |
| Presumptive transmission route, n (%) |                  |
| Men who have sex with men        | 39 (46.4) |
| Heterosexuals                    | 32 (38.1) |
| Intravenous drug users           | 0 (0) |
| Unknown                          | 13 (15.5) |
| Nadir CD4 cell count, median cells/µL (IQR) | 116 (45–245) |
| Current CD4 cell count, median cells/µL (IQR) | 531 (345–762) |
| HIV viral load, n (%)            |                  |
| Undetectable (<40 copies/mL)     | 75 (89.3) |
| < 400 copies/mL                  | 8 (9.5) |
| ≥ 400 copies/mL                  | 1 (1.2) |
| Time since HIV diagnosis, median months (IQR) | 92 (43–135) |
| Duration of antiretroviral therapy, median months (IQR) | 71 (36–120) |
| Positive for hepatitis B antibody, n (%) | 7 (8.3) |
| Positive for hepatitis C antibodies, n (%) | 3 (3.6) |
| Diabetics                        | 15 (17.9) |
| Hyperlipidemia                   | 29 (34.5) |
| Body mass index, median kg/m² (IQR) | 22.5 (20.7–24.3) |
| Smoking, n (%)                   |                  |
| None                             | 50 (59.6) |
| < 1 pack/day                     | 17 (20.2) |
| ≥ 1 pack/day                     | 17 (20.2) |
| Alcohol consumption currently, n (%) |                  |
| < 60 kcal/day                    | 64 (76.2) |
| ≥ 60 kcal/day                    | 20 (23.8) |
| Exercise, n (%)                  |                  |
| None                             | 59 (70.2) |
| Running more than one hour in a week | 25 (29.8) |
| Serum 25(OH) vitamin D level, n (%) |                  |
| Normal (>30 ng/mL)               | 7 (8.3) |
| Insufficiency (20–30 ng/mL)      | 22 (26.2) |
| Deficiency (<20 ng/mL)           | 55 (65.5) |
| Serum carboxyl-terminal collagen crosslinks level, n (%) |                  |
| Normal (<0.3 ng/mL)              | 17 (20.2) |
| Elevated (≥0.3 ng/mL)            | 67 (79.8) |
| Parathyroid hormone, median pg/mL (IQR) | 49.9 (42.8–68.3) |
| Bone-specific alkaline phosphatase, IU/L (IQR) | 33.1 (27–42.1) |
| Total testosterone, ng/mL (IQR)  | 4.7 (3.7–6.5) |
| Free testosterone, pg/mL (IQR)   | 10.4 (7.4–14.4) |

IQR, interquartile range; HIV, human immunodeficiency virus.
BMD and HIV exposure category (between MSM and heterosexual men), CART category (between protease inhibitor-based and non-nucleoside reverse transcriptase inhibitor-based), smoking, alcohol intake or exercise status. BMD was positively associated with BMI at all three sites and these associations were independent of other factors (Table 3). BMD at the femoral neck and total hip was negatively associated with serum CTX and these associations were independent of other factors. Bone specific ALP was negatively associated with lumbar spine BMD in multivariate analysis. The logistic regression analysis revealed that independent risk factors for low BMD were low BMI, high serum CTX, and high bone-specific ALP (Table 4).

**Discussion**

In the present study, BMDs at the lumbar spine, femur neck and total hip were investigated among Korean HIV-positive male patients undergoing CART, and clinical factors and serum markers were measured. Low bone mass was prevalent among Korean HIV-positive male patients undergoing antiretroviral treatment. Several factors were associated with low bone mass.

A high prevalence of low bone mass has been reported in HIV-positive individuals in many cross-sectional studies [7,8]. The prevalence of osteoporosis was more than three times greater among HIV-positive patients than among HIV-negative control subjects in a meta-analysis [4]. A decrease of BMD ranging from −1.5 to −5.8%, depending on the antiretroviral regimen, was observed within the first year of antiretroviral therapy [9]. The overall prevalence of fractures was significantly higher in HIV-positive patients, than in HIV-negative patients (2.87 vs. 1.77 fractures per 100 persons) [10]. Accordingly, in the present study, the patients with HIV infections had significantly lower BMD than age-matched HIV-negative Koreans in the general population. In the present study, the overall prevalence of osteoporosis and osteopenia were 9.5 and 46.4%, respectively. The reported prevalence of osteoporosis in HIV-positive patients varies widely according to age group and gender (3–33%) [3].

Several researchers have reported the prevalence of osteoporosis in HIV-positive men in Western countries (France: 16%, mean age 40 years; Australia: 3%, mean age 43 years) [7,11]. A recent study reported the prevalence of osteoporosis in HIV-positive men in Taiwan (3.1%; median age 36.5 years) [12]. However, as discussed by its authors, the Taiwanese study was limited by several factors (majority of the subjects were middle aged, no bone turnover markers were measured and, most importantly, only lumbar spine BMD was measured, not femur neck or total hip). In addition to these limitations, due to the study design (which excluded potential osteoporosis patients), the authors state that the prevalence of osteoporosis was underestimated. In the present study, the prevalence of osteoporosis was determined using all three BMD sites. And the BMDs of HIV-positive men were compared with those of age-matched same-race controls. The association between BMD and bone-metabolism-related factors including bone turnover markers was also investigated.

The causes of low bone mass in HIV appear to be multifactorial. First, there are complex interactions between HIV infection and traditional osteoporosis risk factors [13]. Chronic HIV infection leads to poor nutrition and low weight. Indeed, the BMI of the HIV-negative control group was 23.8 ± 3.1 and the BMI of the HIV-positive study group was 22.6 ± 2.5. This difference in BMI could explain some portion of the difference in BMD. Low vitamin D levels [14] and hypogonadism [15] are associated with HIV infection. The prevalence of diabetes was high among the study subjects. The high prevalence of diabetes could have a substantial effect on bone metabolism. However, the BMD was not significantly different between diabetic and non-diabetic patients and similar trends were observed when diabetic subjects were excluded. High rates of alcohol and tobacco use are reported among HIV-positive patients. Second, uncontrolled HIV viremia per se may decrease bone mass [4,16]; systemic inflammation caused by HIV infection can affect bone remodelling. There have been several studies of the association between HIV infection and bone remodelling. HIV proteins have been reported to augment bone resorption through increased osteoclast activity [17], and HIV proteins attenuate bone formation by stimulating osteoblasts apoptosis [18]. Third, CART-related factors may also link low bone mass and HIV infection. Continuous CART decreased BMD [19] and intermittent CART resulted in less loss of BMD [20]. These complex mechanisms could have resulted in the low BMD observed in the present study.

We found that low BMD was associated with low BMD at all three sites. Similar findings were obtained in previous studies [11,12], demonstrating the important association between body weight and BMD. Markers of bone metabolism (CTX and bone-specific ALP) were negatively associated with BMD.

### Table 2. Prevalence of low bone mass in the study participants

| Age Group | Normal | Low BMD for chronological age<sup>a</sup> |
|-----------|--------|-----------------------------------------|
| 40–49 age group | | |
| Lumbar spine | 35 (83.3) | 7 (16.7) |
| Femoral neck | 42 (100) | 0 (0) |
| Total hip | 42 (100) | 0 (0) |
| 50–59 age group | | |
| Lumbar spine | 22 (75.9) | 5 (17.2) |
| Femoral neck | 20 (69.0) | 9 (31.0) |
| Total hip | 27 (93.1) | 2 (6.9) |
| 60+ age group | | |
| Lumbar spine | 5 (38.5) | 7 (53.8) |
| Femoral neck | 7 (53.8) | 6 (46.2) |
| Total hip | 11 (84.6) | 2 (15.4) |

<sup>a</sup>Diagnosed using the International Society for Clinical Densitometry (ISCD) Z-score criteria (low BMD for chronological age, Z-score ≤ −2.0).

<sup>b</sup>Diagnosed using the World Health Organization (WHO) T-score criteria (Osteopenia, −2.5 < T-score < −1.0; Osteoporosis, T-score ≤ −2.5). BMD, bone mineral density.
in the present study. This is in accordance with previous studies of HIV-positive patients [21,22], suggesting that high bone turnover is associated with the reduction in BMD. The initiation of CART led to an increase in markers of bone turnover [22] and intermittent application of CART reduced the decline in markers of bone turnover and in BMD [20], suggesting that CART decreases BMD by increasing bone turnover. These findings indicate that measurements of bone turnover markers in HIV-positive patients could be used in the clinic to assess bone metabolism status in HIV.

In the present study, we observed significantly lower femur neck BMD and total hip BMD in HIV-positive patients than in HIV-negative patients in the general Korean population. However, no significant difference was observed in lumbar spine BMD. A previous study also reported that the difference in lumbar spine BMD was borderline whereas the difference in hip BMD was significant [7]. Others have reported that both lumbar spine BMD and femur neck BMD are significantly lower in HIV-positive patients [8].

A recent study showed that intermittent CART has less effect on BMD than continuous antiretroviral therapy [20], which suggests a deleterious effect of CART on bone. Also, longer duration of CART was associated with reduced BMD [12]. However, in the present analysis, the duration of CART was not associated with BMD.

In one recent study, the prevalence of low BMD was similar among HIV-positive MSM and HIV-negative MSM [23], suggesting that the low BMD found in the former may precede HIV acquisition. Compared with heterosexual men, MSM are likely to have the conventional risk factors for osteoporosis (such as low body weight, alcohol use, smoking) [24]. Based on these findings, it has been suggested that the low BMD found among HIV-positive MSM may be the result of MSM-related factors, and may not be fully attributable to HIV infection alone or the use of ART [23]. However, in the present study, there was no significant difference in BMD between MSM and heterosexual men, suggesting that the low BMD is more likely to be the result of HIV infection and/or the use of CART than MSM-related lifestyle factors.

This study has several limitations. First, because of its cross-sectional design, causal relationships between HIV infection and reduced BMD could not be determined. Second, its statistical power was low due to the small sample size. Third, half of the study subjects were under the age of 40.
Table 3. Summary of linear regression analysis of factors associated with bone mineral density

| Variables                        | Lumbar spine Univariate | Lumbar spine Multivariate | Femoral neck Univariate | Femoral neck Multivariate | Total hip Univariate | Total hip Multivariate |
|----------------------------------|-------------------------|---------------------------|-------------------------|---------------------------|----------------------|------------------------|
|                                  | B          | p          | B          | p          | B          | p          | B          | p          | B          | p          | B          | p          |
| Age                              | -0.001    | 0.752     | -          | -          | -0.002    | 0.206     | -          | -          | -0.015    | 0.988     | -          | -          |
| BMI                              | 0.031     | <0.001    | 0.028     | <0.001    | 0.019     | <0.001    | 0.016     | 0.002     | 0.024     | <0.001    | 0.021     | <0.001    |
| Smoking                          | -0.003    | 0.910     | -          | -          | 0.001     | 0.963     | -          | -          | 0.003     | 0.859     | -          | -          |
| Alcohol                          | -0.078    | 0.062     | -0.050    | 0.178     | -0.029    | 0.369     | -          | -          | -0.031    | 0.369     | -          | -          |
| (≥ 60 kcal/day)                  |            |            |            |            |            |            |            |            |            |            |            |            |
| Exercisea                        | -0.050    | 0.198     | -          | -          | -0.023    | 0.436     | -          | -          | -0.039    | 0.218     | -          | -          |
| PI-based regimen ever            | 0.027     | 0.535     | -          | -          | 0.015     | 0.645     | -          | -          | 0.037     | 0.301     | -          | -          |
| ART duration                     | 0.000     | 0.393     | -          | -          | 0.000     | 0.243     | -          | -          | 0.000     | 0.359     | -          | -          |
| Nadir CD4                        | -0.001    | 0.630     | -          | -          | -0.002    | 0.854     | -          | -          | -0.001    | 0.680     | -          | -          |
| Current CD4                      | 0.001     | 0.681     | -          | -          | -0.001    | 0.787     | -          | -          | 0.001     | 0.740     | -          | -          |
| 25(OH) Vitamin D3                | 0.001     | 0.733     | -          | -          | -0.001    | 0.787     | -          | -          | 0.001     | 0.751     | -          | -          |
| PTH                              | 0.001     | 0.111     | -          | -          | 0.001     | 0.976     | -          | -          | 0.000     | 0.631     | -          | -          |
| CTX                              | -0.261    | 0.002     | -0.169    | 0.032     | -0.206    | 0.002     | -0.164    | 0.009     | -0.233    | 0.001     | -0.168    | 0.008     |
| Bone-specific ALP                | -0.002    | 0.112     | -          | -          | -0.001    | 0.210     | -          | -          | -0.001    | 0.161     | -0.001    | 0.086     |
| Testosterone                     | 0.000     | 0.971     | -          | -          | -0.008    | 0.253     | -          | -          | -0.006    | 0.420     | -          | -          |
| Free testosterone               | -0.002    | 0.676     | -          | -          | -0.002    | 0.393     | -          | -          | -0.002    | 0.566     | -          | -          |
| Urine Ca/Cr                      | -0.106    | 0.710     | -0.149    | 0.492     | -          | -          | -0.158    | 0.495     | -          | -          |            |            |

Table 4. Summary of logistic regression analysis of factors associated with low bone mineral density (any T score ≤ −1)

| Variables                          | Univariate ORa | 95% CI       | p       | Multivariate aORa | 95% CI       | p       |
|-----------------------------------|---------------|-------------|--------|------------------|-------------|--------|
| Age                               | 1.330         | 0.847–2.089 | 0.215  |                 |             |        |
| BMI                               | 0.479         | 0.285–0.805 | 0.005  |                 |             |        |
| Smoking                           | 0.961         | 0.562–1.642 | 0.883  |                 |             |        |
| Alcohol (≥ 60 kcal/day)           | 3.000         | 0.974–9.236 | 0.056  |                 |             |        |
| Exerciseb                         | 1.606         | 0.613–4.208 | 0.335  |                 |             |        |
| PI-based regimen ever             | 0.399         | 0.107–1.483 | 0.170  |                 |             |        |
| ART duration                      | 1.004         | 0.651–1.548 | 0.987  |                 |             |        |
| Nadir CD4                         | 1.293         | 0.829–2.018 | 0.258  |                 |             |        |
| Current CD4                       | 1.009         | 0.654–1.556 | 0.968  |                 |             |        |
| 25(OH) Vitamin D3                 | 0.932         | 0.604–1.437 | 0.749  |                 |             |        |
| PTH                               | 1.050         | 0.680–1.623 | 0.825  |                 |             |        |
| CTX                               | 3.125         | 1.572–6.211 | 0.001  | 2.672            | 1.325–5.388 | 0.006  |
| Bone-specific ALP                 | 1.996         | 1.016–3.923 | 0.045  | 2.325            | 1.021–5.291 | 0.044  |
| Testosterone                      | 1.268         | 0.810–1.986 | 0.300  |                 |             |        |
| Free testosterone                | 1.200         | 0.774–1.861 | 0.414  |                 |             |        |
| Urine Ca/Cr                       | 1.238         | 0.788–1.946 | 0.354  |                 |             |        |

aOdds ratios are shown as per one standard deviation increment.

bRunning more than one hour a week.

OR, Odds ratio; CI, confidence interval; BMI, body mass index; PI, protease inhibitor; PTH, parathyroid hormone; CTX, carboxy-terminal collagen crosslinks; ALP, alkaline phosphatase; Ca, calcium; Cr, creatinine.
50 years. Inclusion of these young participants could have attenuated the statistical significance regarding the effect of ageing on bone loss. However, to the best of our knowledge, this is the first study in the English language to report the prevalence of osteoporosis based on all three BMD sites as well as factors related to bone metabolism, including bone turnover markers, in HIV-positive Asian men.

Conclusions

In this first survey for HIV-associated osteopenia in Asians undergoing antiretroviral therapy, the prevalence of low bone mass was significantly higher compared to non-HIV-infected individuals. Low bone mass was associated with increased bone resorption.

Authors’ affiliations

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

Competing interests

The authors do not have any commercial or other connections that might create conflicts of interest.

Authors’ contributions

All investigators contributed to the concept of this study, CPG, WBP, OMD and NJK recruited patients and performed medical interviews. CPG and HJC analyzed the data and wrote the paper. NJK supervised data analysis and revised the manuscript. All other authors critically read and approved the final manuscript.

Acknowledgements

This work was supported by a grant from the Korean Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea (Project No. A110744) and a grant from the research fund of Seoul National University Hospital (Grant No. OS-2010-0010). We thank Dr. Chan Soo Shin for providing scientific advice and a critical review of the study proposal.

References

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–60.
2. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51–8.
3. Powderly WG. Osteoporosis and bone health in HIV. Curr HIV/AIDS Rep. 2012;9:218–22.
4. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20:2165–74.
5. Baim S, Binkey N, Bilezikian JP, Kenderli D, Hans DB, Lewiecki EM, et al. Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom. 2008;11:75–91.
6. Shin CS, Choi HJ, Kim MJ, Kim JT, Yu SH, Koo BK, et al. Prevalence and risk factors of osteoporosis in Korea: a community-based cohort study with lumbar spine and hip bone mineral density. Bone. 2010;47:378–87.
7. Jones S, Restrepo D, Kasowitz A, Korenstein D, Wallenstein S, Schneider A, et al. Risk factors for decreased bone density and effects of HIV on bone in the elderly. Osteoporos Int. 2008;19:913–8.
8. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo Y, Klein RS. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS. 2007;21:617–23.
9. Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS. 2009;23:817–24.
10. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus HIV-negative patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008;93:3499–504.
11. Carr A, Miller J, Eisman JA, Cooper DA. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS. 2001;15:703–9.
12. Tsiak MS, Hung CC, Liu WC, Chen KL, Chen MY, Hsieh SM, et al. Reduced bone mineral density among HIV-infected patients in Taiwan: prevalence and associated factors. J Microbiol Immunol Infect. 2012. Available from: http://www.ncbi.nlm.nih.gov/pubmed/?term=23073318.
13. McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis. 2010;51:937–46.
14. Rodriguez M, Daniels B, Gunawardene S, Robbins GK. High frequency of vitamin D deficiency in ambulatory HIV-positive patients. AIDS Res Hum Retroviruses. 2009;25:9–14.
15. Teichmann J, Lange U, Discher T, Lohmeyer J, Stracke H, Bretzel RG. Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART). Eur J Med Res. 2009;14:59–64.
16. Bruera D, Luna N, David OQ, Berggoll GM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS. 2003;17:1917–23.
17. Fakrudin JM, Laurence J. HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol. 2005;150:67–78.
18. Gibellini D, De Cignis E, Ponti C, Cimatti L, Borderi M, Tschon M, et al. HIV-1 triggers apoptosis in primary osteoblasts and HOIB cells through TNFalpha activation. J Med Virol. 2008;80:1507–14.
19. Grund B, Beng G, Gilbert CL, Hoy JF, Ikasslin RL, Shilay JC, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS. 2009;23:1519–29.
20. Hoy J, Grund B, Roediger M, Ensrud KE, Brar I, Colebunders R, et al. Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: the SMART body composition substudy. J Bone Miner Res. 2013;28:1264–74.
21. Amiel C, Ostertag A, Slama L, Baudoin C, NGuyenn T, Lajeunie E, et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res. 2004;19:402–9.
22. Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaarden E, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51:963–72.
23. Grijzen ML, Vrouenraets SM, Wit FW, Stolte IG, Prins M, Lips P, et al. Low bone mineral density, regardless of HIV status, in men who have sex with men. J Infect Dis. 2013;207:386–91.
24. Stall R, Paul JP, Greenwood G, Pollack LM, Bein E, Crosby GM, et al. Alcohol use, drug use and alcohol-related problems among men who have sex with men: the Urban Men’s Health Study. Addiction. 2003;96:1589–601.